We are live on ! Find out more
XBIO icon

Xenetic Biosciences
XBIO

19 hedge funds and large institutions have $198K invested in Xenetic Biosciences in 2022 Q4 according to their latest regulatory filings, with 7 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

75% more first-time investments, than exits

New positions opened: 7 | Existing positions closed: 4

19% more funds holding

Funds holding: 16 → 19 (+3)

0.24% less ownership

Funds ownership: 0.69% → 0.46% (-0.24%)

33% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 3

63% less capital invested

Capital invested by funds: $535K → $198K (-$337K)

Holders
19
Holders Change
+3
Holders Change %
+18.75%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
2
Reduced
3
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
HF
HRT Financial
New York
+$24.9K
2
Jane Street
Jane Street
New York
+$17.5K
3
Citadel Advisors
Citadel Advisors
Florida
+$14.3K
4
Renaissance Technologies
Renaissance Technologies
New York
+$12.5K
5
Susquehanna International Group
Susquehanna International Group
Pennsylvania
+$11K

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$202K
2
VF
Virtu Financial
New York
-$11K
3
TSS
Two Sigma Securities
New York
-$8K
4
UBS Group
UBS Group
Switzerland
-$4K
5
TRCT
Tower Research Capital (TRC)
New York
-$150
Name Holding Trade Value Shares
Change 		Change in
Stake
Vanguard Group
1
Vanguard Group
Pennsylvania
$45.2K -$202K -45,785 -74%
Renaissance Technologies
2
Renaissance Technologies
New York
$41K +$12.5K +2,830 +25%
Geode Capital Management
3
Geode Capital Management
Massachusetts
$26K -$114 -26 -0.3%
HF
4
HRT Financial
New York
$16K +$24.9K +5,647 New
Jane Street
5
Jane Street
New York
$11.3K +$17.5K +3,977 New
State Street
6
State Street
Massachusetts
$9.91K – – –
Citadel Advisors
7
Citadel Advisors
Florida
$9.31K +$14.3K +3,257 New
JEST
8
JTC Employer Solutions Trustee
Jersey
$8K – – –
Susquehanna International Group
9
Susquehanna International Group
Pennsylvania
$7.16K +$11K +2,504 New
SPIA
10
Steward Partners Investment Advisory
New York
$5.42K – – –
E
11
Ergoteles
New York
$5.38K +$8.29K +1,883 New
Northern Trust
12
Northern Trust
Illinois
$5.06K – – –
GVAG
13
Great Valley Advisor Group
Delaware
$3.02K – – –
TRCT
14
Tower Research Capital (TRC)
New York
$3K -$150 -34 -3%
Morgan Stanley
15
Morgan Stanley
New York
$1.7K +$9 +2 +0.3%
NC
16
NewSquare Capital
Pennsylvania
$74 +$114 +26 New
Wells Fargo
17
Wells Fargo
California
$29 – – –
Fidelity Investments
18
Fidelity Investments
Massachusetts
$5 – – –
VF
19
Virtu Financial
New York
– -$11K -1,973 Closed
TSS
20
Two Sigma Securities
New York
– -$8K -1,396 Closed
UBS Group
21
UBS Group
Switzerland
– -$4K -786 Closed
Royal Bank of Canada
22
Royal Bank of Canada
Ontario, Canada
– +$132 +30 New

XBIO Hedge Fund Activity: Q4 2022 in Review

19 of the 6,222 institutional investors tracked by Wall St. Rank reported a position in Xenetic Biosciences (XBIO) for Q4 2022, worth a combined $198K — down 63% from $535K a quarter earlier.

Buyers outnumbered sellers: 7 funds opened new XBIO positions and 4 closed out — a net gain of 3 holders — while 2 added to existing stakes and 3 trimmed.

The largest buyer was HRT Financial, opening a new position worth an estimated $24.9K. The largest seller was Vanguard Group, cutting an estimated $202K.

  • 19 institutional investors held Xenetic Biosciences (XBIO) as of Q4 2022, up from 16 in Q3 2022.
  • Funds reported $198K of Xenetic Biosciences stock for Q4 2022, down 63% quarter-over-quarter.
  • 7 funds opened new Xenetic Biosciences positions in Q4 2022 and 4 closed out, a net change of +3 holders.
  • The largest Xenetic Biosciences buyer in Q4 2022 was HRT Financial, an estimated $24.9K added.
  • The largest Xenetic Biosciences seller in Q4 2022 was Vanguard Group, an estimated $202K sold.

Based on aggregated 13F filings for Q4 2022.